{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:40:57Z","timestamp":1790602857159,"version":"4.1.0"},"reference-count":146,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.4065\/84.8.741","type":"journal-article","created":{"date-parts":[[2009,7,31]],"date-time":"2009-07-31T17:27:42Z","timestamp":1249061262000},"page":"741-757","source":"Crossref","is-referenced-by-count":101,"title":["Primary and Secondary Prevention of Cardiovascular Diseases: A Practical Evidence-Based Approach"],"prefix":"10.4065","volume":"84","author":[{"given":"James H.","family":"O'Keefe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maia D.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J.","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.4065\/84.8.741_bib1","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.jacc.2008.05.051","article-title":"A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease","volume":"52","author":"Sch\u00f6mig","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.4065\/84.8.741_bib2","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1056\/NEJMc071317","article-title":"PCI for stable coronary disease [letter]","volume":"357","author":"Katritsis","year":"2007","journal-title":"N Engl J Med"},{"issue":"15","key":"10.4065\/84.8.741_bib3","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","article-title":"Optimal medical therapy with or without PCI for stable coronary disease","volume":"356","author":"Boden","year":"2007","journal-title":"N Engl J Med"},{"issue":"24","key":"10.4065\/84.8.741_bib4","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMoa0805796","article-title":"A randomized trial of therapies for type 2 diabetes and coronary artery disease","volume":"360","author":"Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"10.4065\/84.8.741_bib5","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.2967\/jnumed.107.038661","article-title":"Role of inflammation in atherosclerosis","volume":"48","author":"Spagnoli","year":"2007","journal-title":"J Nucl Med"},{"issue":"12","key":"10.4065\/84.8.741_bib6","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1001\/jama.297.12.1376","article-title":"Primary prevention of atherosclerotic cardiovascular disease: the high public burden of low individual risk [editorial]","volume":"297","author":"Lauer","year":"2007","journal-title":"JAMA"},{"issue":"2A","key":"10.4065\/84.8.741_bib7","doi-asserted-by":"crossref","first-page":"2H","DOI":"10.1016\/j.amjcard.2006.03.002","article-title":"From vulnerable plaque to vulnerable patient, Part III: executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report","volume":"98","author":"Naghavi","year":"2006","journal-title":"Am J Cardiol"},{"issue":"13","key":"10.4065\/84.8.741_bib8","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa072100","article-title":"Coronary calcium as a predictor of coronary events in four racial or ethnic groups","volume":"358","author":"Detrano","year":"2008","journal-title":"N Engl J Med"},{"issue":"23","key":"10.4065\/84.8.741_bib9","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1056\/NEJMsa053935","article-title":"Explaining the decrease in U.S. deaths from coronary disease, 1980-2000","volume":"356","author":"Ford","year":"2007","journal-title":"N Engl J Med"},{"issue":"14","key":"10.4065\/84.8.741_bib10","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1001\/jama.297.14.1551","article-title":"Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study","volume":"297","author":"Morgan","year":"2007","journal-title":"JAMA"},{"issue":"9438","key":"10.4065\/84.8.741_bib11","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"issue":"10","key":"10.4065\/84.8.741_bib12","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.jacc.2005.02.051","article-title":"The optimal low-density lipoprotein is 50 to 70 mg\/dl [letter]","volume":"45","author":"Clendenning","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10.4065\/84.8.741_bib13","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2008.12.068","article-title":"Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss","volume":"53","author":"Lavie","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.4065\/84.8.741_bib14","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jacc.2008.04.067","article-title":"Obesity and age of first non-ST-segment elevation myocardial infarction","volume":"52","author":"Madala","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10.4065\/84.8.741_bib15","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report [published correction appears in JAMA. 2003;290(2):197]","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"issue":"15","key":"10.4065\/84.8.741_bib16","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","article-title":"Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"283","year":"2000","journal-title":"JAMA"},{"issue":"6","key":"10.4065\/84.8.741_bib17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1524-6175.2002.02045.x","article-title":"Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"4","author":"Cushman","year":"2002","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"9349","key":"10.4065\/84.8.741_bib18","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"7653","key":"10.4065\/84.8.741_bib19","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/bmj.39548.738368.BE","article-title":"Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials","volume":"336","year":"2008","journal-title":"BMJ"},{"issue":"suppl 1","key":"10.4065\/84.8.741_bib20","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.2337\/diacare.26.2007.S80","article-title":"Treatment of hypertension in adults with diabetes","volume":"26","author":"American Diabetes Association","year":"2003","journal-title":"Diabetes Care"},{"issue":"3","key":"10.4065\/84.8.741_bib21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","journal-title":"N Engl J Med"},{"issue":"9386","key":"10.4065\/84.8.741_bib22","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","author":"EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators","year":"2003","journal-title":"Lancet"},{"issue":"9638","key":"10.4065\/84.8.741_bib23","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"issue":"9311","key":"10.4065\/84.8.741_bib24","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet"},{"issue":"7","key":"10.4065\/84.8.741_bib25","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMoa021716","article-title":"A comparison of outcomes with angiotensin-converting\u2013enzyme inhibitors and diuretics for hypertension in the elderly","volume":"348","author":"Wing","year":"2003","journal-title":"N Engl J Med"},{"issue":"9489","key":"10.4065\/84.8.741_bib26","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"Dahl\u00f6f","year":"2005","journal-title":"Lancet"},{"issue":"23","key":"10.4065\/84.8.741_bib27","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","author":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"issue":"9426","key":"10.4065\/84.8.741_bib28","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"issue":"6","key":"10.4065\/84.8.741_bib29","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.ejheart.2008.05.003","article-title":"Clinical trials update from the American College of Cardiology 2008: CARISMA, TRENDS, meta-analysis of Cox-2 studies, HAT, ON-TARGET, HYVET, ACCOMPLISH, MOMENTUM, PROTECT, HORIZON-HF and REVERSE","volume":"10","author":"Cleland","year":"2008","journal-title":"Eur J Heart Fail"},{"issue":"23","key":"10.4065\/84.8.741_bib30","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N Engl J Med"},{"issue":"18","key":"10.4065\/84.8.741_bib31","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","article-title":"Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial","volume":"292","author":"Bakris","year":"2004","journal-title":"JAMA"},{"issue":"1","key":"10.4065\/84.8.741_bib32","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/01.HYP.0000103632.19915.0E","article-title":"Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability","volume":"43","author":"Carter","year":"2004","journal-title":"Hypertension"},{"issue":"3","key":"10.4065\/84.8.741_bib33","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/01.HYP.0000203309.07140.d3","article-title":"Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure","volume":"47","author":"Ernst","year":"2006","journal-title":"Hypertension"},{"issue":"24","key":"10.4065\/84.8.741_bib34","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1001\/jama.1991.03460240051027","article-title":"Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP)","volume":"265","author":"SHEP Cooperative Research Group","year":"1991","journal-title":"JAMA"},{"issue":"5","key":"10.4065\/84.8.741_bib35","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1161\/01.CIR.82.5.1616","article-title":"Mortality after 10 1\/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial","volume":"82","author":"Multiple Risk Factor Intervention Trial Research Group","year":"1990","journal-title":"Circulation"},{"key":"10.4065\/84.8.741_bib36","series-title":"Diabetes Essentials","first-page":"191","author":"O'Keefe","year":"2009"},{"issue":"14","key":"10.4065\/84.8.741_bib37","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [published correction appears in N Engl J Med. 2003;348(22):2271]","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"issue":"10","key":"10.4065\/84.8.741_bib38","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"8","key":"10.4065\/84.8.741_bib39","doi-asserted-by":"crossref","first-page":"718","DOI":"10.4065\/84.8.718","article-title":"\u03b2-Blocker use for the stages of heart failure","volume":"84","author":"Klapholz","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"18","key":"10.4065\/84.8.741_bib40","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.jacc.2008.08.008","article-title":"Beta-blockers in hypertension: adding insult to injury [editorial]","volume":"52","author":"Kaplan","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"9446","key":"10.4065\/84.8.741_bib41","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(04)17355-8","article-title":"Atenolol in hypertension: is it a wise choice","volume":"364","author":"Carlberg","year":"2004","journal-title":"Lancet"},{"issue":"9377","key":"10.4065\/84.8.741_bib42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"},{"issue":"11","key":"10.4065\/84.8.741_bib43","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1524-6175.2007.07548.x","article-title":"The efficacy and tolerability of nebivolol in hypertensive African American patients","volume":"9","author":"Saunders","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"1","key":"10.4065\/84.8.741_bib44","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/0003-4819-147-1-200707030-00003","article-title":"\u03b2-Blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials","volume":"147","author":"Sipahi","year":"2007","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.4065\/84.8.741_bib45","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jacc.2007.08.055","article-title":"Shedding light on high-density lipoprotein cholesterol: the post-ILLUMINATE era [editorial]","volume":"51","author":"Lavie","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"9607","key":"10.4065\/84.8.741_bib46","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","year":"2008","journal-title":"Lancet"},{"issue":"9326","key":"10.4065\/84.8.741_bib47","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"11","key":"10.4065\/84.8.741_bib48","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.jacc.2004.03.046","article-title":"Optimal low-density lipoprotein is 50 to 70 mg\/dl: lower is better and physiologically normal","volume":"43","author":"O'Keefe","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.4065\/84.8.741_bib49","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2005.04.064","article-title":"Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy","volume":"46","author":"Wiviott","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"10.4065\/84.8.741_bib50","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.4065\/84.8.741_bib51","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1185\/030079908X292001","article-title":"Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin","volume":"24","author":"Bybee","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"19","key":"10.4065\/84.8.741_bib52","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"issue":"11","key":"10.4065\/84.8.741_bib53","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"issue":"13","key":"10.4065\/84.8.741_bib54","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"issue":"9","key":"10.4065\/84.8.741_bib55","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"issue":"21","key":"10.4065\/84.8.741_bib56","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"issue":"18","key":"10.4065\/84.8.741_bib57","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","article-title":"A randomized trial of rosuvastatin in the prevention of venous thromboembolism","volume":"360","author":"Glynn","year":"2009","journal-title":"N Engl J Med"},{"issue":"9364","key":"10.4065\/84.8.741_bib58","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"issue":"9435","key":"10.4065\/84.8.741_bib59","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"issue":"10","key":"10.4065\/84.8.741_bib60","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/ncpcardio1322","article-title":"The use of high-sensitivity assays for C-reactive protein in clinical practice","volume":"5","author":"Musunuru","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"11","key":"10.4065\/84.8.741_bib61","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jacc.2008.12.010","article-title":"Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.","volume":"53","author":"Michos","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.4065\/84.8.741_bib62","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0025-6196(11)60548-X","article-title":"Exercise training and cardiac rehabilitation in primary and secondary prevention of coronary heart disease","volume":"84","author":"Lavie","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.4065\/84.8.741_bib63","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0002-9149(03)00464-8","article-title":"Prevalence and profile of metabolic syndrome in patients following acute coronary events and effects of therapeutic lifestyle change with cardiac rehabilitation","volume":"92","author":"Milani","year":"2003","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.4065\/84.8.741_bib64","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.jacc.2003.10.041","article-title":"Reduction in C-reactive protein through cardiac rehabilitation and exercise training","volume":"43","author":"Milani","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10.4065\/84.8.741_bib65","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIRCULATIONAHA.108.773747","article-title":"Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden","volume":"117","author":"Ballantyne","year":"2008","journal-title":"Circulation"},{"issue":"13","key":"10.4065\/84.8.741_bib66","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","article-title":"Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial","volume":"295","author":"Nissen","year":"2006","journal-title":"JAMA"},{"issue":"12","key":"10.4065\/84.8.741_bib67","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.297.12.1344","article-title":"Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial","volume":"297","author":"Crouse","year":"2007","journal-title":"JAMA"},{"issue":"8","key":"10.4065\/84.8.741_bib68","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0025-6196(11)60762-3","article-title":"Intensive lipid intervention in the post-ENHANCE era [editorial]","volume":"83","author":"O'Keefe","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.4065\/84.8.741_bib69","doi-asserted-by":"crossref","first-page":"218","DOI":"10.4065\/84.3.218","article-title":"Carotid intima-media thickness: can it close the \u201cdetection gap\u201d for cardiovascular risk [editorial]?","volume":"84","author":"Gerber","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.4065\/84.8.741_bib70","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4065\/84.3.229","article-title":"Carotid intima-media thickness and coronary artery calcium score as indications of subclinical atherosclerosis","volume":"84","author":"Lester","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.4065\/84.8.741_bib71","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ahj.2007.06.034","article-title":"Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors","volume":"154","year":"2007","journal-title":"Am Heart J"},{"issue":"3","key":"10.4065\/84.8.741_bib72","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3810\/pgm.2009.05.2010","article-title":"The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin)","volume":"121","author":"O'Keefe","year":"2009","journal-title":"Postgrad Med"},{"issue":"19","key":"10.4065\/84.8.741_bib73","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","article-title":"AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"issue":"8","key":"10.4065\/84.8.741_bib74","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.amjcard.2005.11.039","article-title":"Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia [published correction appears in Am J Cardiol. 2006;98(3):428]","volume":"97","author":"Bays","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.4065\/84.8.741_bib75","unstructured":"Bell DS, O'Keefe JH. Rediscovering bile acid sequestrants. Diabetes Obes Metab. In press."},{"issue":"3","key":"10.4065\/84.8.741_bib76","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jacc.2007.10.016","article-title":"Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health","volume":"51","author":"O'Keefe","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.4065\/84.8.741_bib77","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.amjcard.2005.08.070","article-title":"Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project)","volume":"97","author":"Canner","year":"2006","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.4065\/84.8.741_bib78","doi-asserted-by":"crossref","first-page":"470","DOI":"10.4065\/83.4.470","article-title":"Effects of niacin on glucose control in patients with dyslipidemia","volume":"83","author":"Goldberg","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.4065\/84.8.741_bib79","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jacl.2007.05.003","article-title":"Niacin plus simvastatin reduces coronary stenosis progression among patients with metabolic syndrome despite a modest increase in insulin resistance: a subgroup analysis of the HDL-Atherosclerosis Treatment Study (HATS)","volume":"1","author":"Vittone","year":"2007","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.4065\/84.8.741_bib80","first-page":"239","article-title":"The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management","volume":"9","author":"Cardenas","year":"2008","journal-title":"Rev Cardiovasc Med"},{"issue":"3","key":"10.4065\/84.8.741_bib81","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.amjcard.2005.03.076","article-title":"Frequency of undiagnosed diabetes mellitus in patients with acute coronary syndrome","volume":"96","author":"Conaway","year":"2005","journal-title":"Am J Cardiol"},{"issue":"9131","key":"10.4065\/84.8.741_bib82","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"issue":"24","key":"10.4065\/84.8.741_bib83","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"The Action to Control Cardiovascular Risk in Diabetes Study Group","year":"2008","journal-title":"N Engl J Med"},{"issue":"3 suppl","key":"10.4065\/84.8.741_bib84","first-page":"9","article-title":"Advances in diabetes for the millennium: drug therapy of type 2 diabetes","volume":"6","author":"Rendell","year":"2004","journal-title":"MedGenMed"},{"issue":"6","key":"10.4065\/84.8.741_bib85","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Diabetes Prevention Program Research Group","year":"2002","journal-title":"N Engl J Med"},{"issue":"23","key":"10.4065\/84.8.741_bib86","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [published correction appears in N Engl J Med. 2007;356(13):1387-1388]","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.4065\/84.8.741_bib87","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/157016307781115476","article-title":"Diabetes beyond insulin: review of new drugs for treatment of diabetes mellitus","volume":"4","author":"Modi","year":"2007","journal-title":"Curr Drug Discov Technol"},{"issue":"3","key":"10.4065\/84.8.741_bib88","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2337\/diacare.26.3.881","article-title":"Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c)","volume":"26","author":"Monnier","year":"2003","journal-title":"Diabetes Care"},{"issue":"1","key":"10.4065\/84.8.741_bib89","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4158\/EP.14.1.112","article-title":"Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events?","volume":"14","author":"Bell","year":"2008","journal-title":"Endocr Pract"},{"issue":"5","key":"10.4065\/84.8.741_bib90","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.amjcard.2007.03.107","article-title":"Postprandial hyperglycemia\/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor","volume":"100","author":"O'Keefe","year":"2007","journal-title":"Am J Cardiol"},{"issue":"9323","key":"10.4065\/84.8.741_bib91","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0140-6736(02)08905-5","article-title":"Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial","volume":"359","author":"Chiasson","year":"2002","journal-title":"Lancet"},{"issue":"9374","key":"10.4065\/84.8.741_bib92","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.4065\/84.8.741_bib93","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2337\/diacare.28.5.1151","article-title":"Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial\u2013lipid-lowering arm (ASCOT-LLA)","volume":"28","author":"Sever","year":"2005","journal-title":"Diabetes Care"},{"issue":"7160","key":"10.4065\/84.8.741_bib94","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"issue":"9200","key":"10.4065\/84.8.741_bib95","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy","volume":"355","author":"Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","journal-title":"Lancet"},{"issue":"15","key":"10.4065\/84.8.741_bib96","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"ONTARGET Investigators","year":"2008","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.4065\/84.8.741_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.13.S1.1","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus","volume":"13","author":"Rodbard","year":"2007","journal-title":"Endocr Pract"},{"issue":"6","key":"10.4065\/84.8.741_bib98","doi-asserted-by":"crossref","first-page":"396","DOI":"10.7326\/0003-4819-150-6-200903170-00008","article-title":"Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement","volume":"150","author":"US Preventive Services Task Force","year":"2009","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.4065\/84.8.741_bib99","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-150-6-200903170-00009","article-title":"Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force","volume":"150","author":"Wolff","year":"2009","journal-title":"Ann Intern Med"},{"issue":"9678","key":"10.4065\/84.8.741_bib100","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","year":"2009","journal-title":"Lancet"},{"issue":"18","key":"10.4065\/84.8.741_bib101","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial [published correction appears in JAMA. 2009;301(18):1882]","volume":"300","author":"Ogawa","year":"2008","journal-title":"JAMA"},{"issue":"6","key":"10.4065\/84.8.741_bib102","doi-asserted-by":"crossref","first-page":"379","DOI":"10.7326\/0003-4819-150-6-200903170-00006","article-title":"Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding","volume":"150","author":"Steinhubl","year":"2009","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.4065\/84.8.741_bib103","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1001\/jama.290.1.86","article-title":"Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review","volume":"290","author":"Critchley","year":"2003","journal-title":"JAMA"},{"issue":"9536","key":"10.4065\/84.8.741_bib104","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0140-6736(06)69249-0","article-title":"Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study","volume":"36","author":"Teo","year":"2006","journal-title":"Lancet"},{"issue":"10","key":"10.4065\/84.8.741_bib105","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.jacc.2006.04.026","article-title":"AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute","volume":"47","author":"Smith","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.4065\/84.8.741_bib106","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.amepre.2008.04.009","article-title":"A clinical practice guideline for treating tobacco use and dependence: 2008 update: a U.S. Public Health Service report","volume":"35","author":"The Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff","year":"2008","journal-title":"Am J Prev Med"},{"issue":"4","key":"10.4065\/84.8.741_bib107","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1751-7141.2008.00003.x","article-title":"A longer course of varenicline therapy improves smoking cessation rates","volume":"11","author":"Lee","year":"2008","journal-title":"Prev Cardiol"},{"issue":"9492","key":"10.4065\/84.8.741_bib108","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0140-6736(05)67483-1","article-title":"Obesity","volume":"366","author":"Haslam","year":"2005","journal-title":"Lancet"},{"issue":"14","key":"10.4065\/84.8.741_bib109","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1001\/jama.288.14.1723","article-title":"Prevalence and trends in obesity among US adults, 1999-2000","volume":"288","author":"Flegal","year":"2002","journal-title":"JAMA"},{"issue":"9497","key":"10.4065\/84.8.741_bib110","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/S0140-6736(05)67663-5","article-title":"Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study","volume":"366","author":"Yusuf","year":"2005","journal-title":"Lancet"},{"issue":"20","key":"10.4065\/84.8.741_bib111","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1056\/NEJMoa0801891","article-title":"General and abdominal adiposity and risk of death in Europe","volume":"359","author":"Pischon","year":"2008","journal-title":"N Engl J Med"},{"issue":"7","key":"10.4065\/84.8.741_bib112","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/eurheartj\/ehm026","article-title":"Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies","volume":"28","author":"de Koning","year":"2007","journal-title":"Eur Heart J"},{"issue":"3","key":"10.4065\/84.8.741_bib113","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/ajcn\/81.3.555","article-title":"Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men","volume":"81","author":"Wang","year":"2005","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"10.4065\/84.8.741_bib114","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1210\/jc.2006-0254","article-title":"Accuracy of anthropometric indicators of obesity to predict cardiovascular risk","volume":"92","author":"Schneider","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.4065\/84.8.741_bib115","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00125-006-0203-x","article-title":"Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus","volume":"49","author":"Bonora","year":"2006","journal-title":"Diabetologia"},{"issue":"3","key":"10.4065\/84.8.741_bib116","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2337\/diacare.29.03.06.dc05-2009","article-title":"Power spectral analysis of heart rate variability during the 100-g oral glucose tolerance test in pregnant women","volume":"29","author":"Weissman","year":"2006","journal-title":"Diabetes Care"},{"issue":"1","key":"10.4065\/84.8.741_bib117","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1161\/CIRCULATIONAHA.106.176158","article-title":"Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee","volume":"114","author":"Lichtenstein","year":"2006","journal-title":"Circulation"},{"issue":"11","key":"10.4065\/84.8.741_bib118","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/archinte.167.11.1195","article-title":"Effect of a traditional Mediterranean diet on lipoprotein oxidation: a randomized controlled trial","volume":"167","author":"Fit\u00f3","year":"2007","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.4065\/84.8.741_bib119","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/ajh.2009.10","article-title":"Association between a DASH-like diet and mortality in adults with hypertension: findings from a population-based follow-up study","volume":"22","author":"Parikh","year":"2009","journal-title":"Am J Hypertens"},{"key":"10.4065\/84.8.741_bib120","unstructured":"Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases\u2014a fish tale with growing credibility. J Am Coll Cardiol. In press."},{"issue":"3","key":"10.4065\/84.8.741_bib121","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4065\/83.3.324","article-title":"Omega-3 fatty acids for cardioprotection","volume":"83","author":"Lee","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"9567","key":"10.4065\/84.8.741_bib122","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"issue":"11","key":"10.4065\/84.8.741_bib123","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jacc.2007.04.089","article-title":"Alcohol and cardiovascular health: the razor-sharp double-edged sword","volume":"50","author":"O'Keefe","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"10.4065\/84.8.741_bib124","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/archinte.166.22.2437","article-title":"Alcohol dosing and total mortality in men and women: an updated meta-analysis of 34 prospective studies","volume":"166","author":"Di Castelnuovo","year":"2006","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.4065\/84.8.741_bib125","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/0003-4819-146-1-200701020-00004","article-title":"Alcohol consumption and risk for coronary heart disease among men with hypertension","volume":"146","author":"Beulens","year":"2007","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.4065\/84.8.741_bib126","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/hrt.2003.016337","article-title":"C Reactive protein, moderate alcohol consumption, and long term prognosis after successful coronary stenting: four year results from the GENERATION study","volume":"90","author":"Zairis","year":"2004","journal-title":"Heart"},{"issue":"6","key":"10.4065\/84.8.741_bib127","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1161\/01.HYP.0000218586.21932.3c","article-title":"Alcohol and hypertension: an update","volume":"47","author":"Beilin","year":"2006","journal-title":"Hypertension"},{"issue":"5","key":"10.4065\/84.8.741_bib128","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/jnci\/djn514","article-title":"Moderate alcohol intake and cancer incidence in women","volume":"101","author":"Allen","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.4065\/84.8.741_bib129","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4065\/81.3.353","article-title":"High prevalence of vitamin D inadequacy and implications for health","volume":"81","author":"Holick","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.4065\/84.8.741_bib130","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJMra070553","article-title":"Vitamin D deficiency","volume":"357","author":"Holick","year":"2007","journal-title":"N Engl J Med"},{"issue":"11","key":"10.4065\/84.8.741_bib131","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1001\/archinte.168.11.1174","article-title":"25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study","volume":"168","author":"Giovannucci","year":"2008","journal-title":"Arch Intern Med"},{"issue":"24","key":"10.4065\/84.8.741_bib132","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.jacc.2008.08.050","article-title":"Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor?","volume":"52","author":"Lee","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.4065\/84.8.741_bib133","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/archinte.168.12.1340","article-title":"Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality","volume":"168","author":"Dobnig","year":"2008","journal-title":"Arch Intern Med"},{"issue":"16","key":"10.4065\/84.8.741_bib134","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1001\/archinte.167.16.1730","article-title":"Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials","volume":"167","author":"Autier","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.4065\/84.8.741_bib135","first-page":"S470","article-title":"Vitamin D deficiency is associated with myalgias in hyperlipidemic subjects taking statins [abstract 3701]","volume":"118","author":"Barton Duell","year":"2008","journal-title":"Circulation"},{"issue":"1","key":"10.4065\/84.8.741_bib136","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s12019-004-0022-2","article-title":"Psychosocial stress and cardiovascular disease: how to heal a broken heart","volume":"30","author":"O'Keefe","year":"2004","journal-title":"Compr Ther"},{"issue":"2","key":"10.4065\/84.8.741_bib137","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jacc.2007.09.033","article-title":"Anxiety characteristics independently and prospectively predict myocardial infarction in men: the unique contribution of anxiety among psychologic factors","volume":"51","author":"Shen","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.4065\/84.8.741_bib138","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11883-006-0048-2","article-title":"Behavioral cardiology: recognizing and addressing the profound impact of psychosocial stress on cardiovascular health","volume":"8","author":"Das","year":"2006","journal-title":"Curr Atheroscler Rep"},{"issue":"12","key":"10.4065\/84.8.741_bib139","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.4065\/81.12.1541","article-title":"Prediction of all-cause mortality by the Minnesota Multiphasic Personality Inventory Optimism-Pessimism Scale scores: study of a college sample during a 40-year follow-up period","volume":"81","author":"Brummett","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.4065\/84.8.741_bib140","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archinte.167.2.174","article-title":"Psychosocial factors and inflammation in the multi-ethnic study of atherosclerosis","volume":"167","author":"Ranjit","year":"2007","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.4065\/84.8.741_bib141","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1207\/s15324796abm3202_9","article-title":"Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute working group report","volume":"32","author":"Davidson","year":"2006","journal-title":"Ann Behav Med"},{"issue":"17","key":"10.4065\/84.8.741_bib142","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1161\/CIRCULATIONAHA.108.190769","volume":"118","author":"Lichtman","year":"2008","journal-title":"Circulation"},{"issue":"5","key":"10.4065\/84.8.741_bib143","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jacc.2004.12.005","article-title":"The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: the emerging field of behavioral cardiology","volume":"45","author":"Rozanski","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.4065\/84.8.741_bib144","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jacc.2008.12.009","article-title":"Do depression or antidepressants increase cardiovascular mortality? The absence of proof might be more important than the proof of absence [editorial]","volume":"53","author":"Narayan","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.4065\/84.8.741_bib145","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.amjmed.2007.03.026","article-title":"Impact of cardiac rehabilitation on depression and its associated mortality","volume":"120","author":"Milani","year":"2007","journal-title":"Am J Med"},{"key":"10.4065\/84.8.741_bib146","unstructured":"Milani RV, Lavie CJ. Reducing psychosocial stress: a novel mechanism of improving survival from exercise training. Am J Med. In press."}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611605259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611605259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T06:09:52Z","timestamp":1685081392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611605259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":146,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0025619611605259"],"URL":"https:\/\/doi.org\/10.4065\/84.8.741","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}